Your browser doesn't support javascript.
loading
Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study.
Dauriat, Gaëlle; Beaumont, Laurence; Luong Nguyen, Liem Binh; Renaud Picard, Benjamin; Penhouet, Morgane; Coiffard, Benjamin; Salpin, Mathilde; Demant, Xavier; Saint Raymond, Christel; Carlier, Nicolas; Messika, Jonathan; Reynaud Gaubert, Martine; Danner, Isabelle; Gallais, Floriane; Roux, Antoine; Le Pavec, Jérôme.
Afiliación
  • Dauriat G; Service de Pneumologie et Transplantation Pulmonaire, Hôpital Marie Lannelogue, Groupe Hospitalier Paris-Saint Joseph, Le Plessis-Robinson, France.
  • Beaumont L; Service de Transplantation Pulmonaire et Centre de Compétence de la Mucoviscidose, Hôpital Foch, Suresnes, France.
  • Luong Nguyen LB; These authors contributed equally to this work.
  • Renaud Picard B; Inserm, CIC 1417, Hôpital Cochin, AP-HP, Paris, France.
  • Penhouet M; These authors contributed equally to this work.
  • Coiffard B; Service de Pneumologie, Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Salpin M; Service de Pneumologie, Institut du Thorax, CHU Nantes, Nantes, France.
  • Demant X; Service de Pneumologie et Equipe de Transplantation Pulmonaire, CHU Nord, AP-HM, Aix-Marseille Université, Marseille, France.
  • Saint Raymond C; Service de Pneumologie, Hôpital Bichat, AP-HP, Paris, France.
  • Carlier N; Service de Pneumologie, Hôpital Haut-Lévêque, Université de Bordeaux, Pessac, France.
  • Messika J; Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble, INSERM1055, Université Grenoble Alpes, Grenoble, France.
  • Reynaud Gaubert M; Service de Pneumologie, Hôpital Cochin, AP-HP, APHP-CUP, Paris, France.
  • Danner I; Service de Pneumologie, Hôpital Bichat, AP-HP, Paris, France.
  • Gallais F; Service de Pneumologie et Equipe de Transplantation Pulmonaire, CHU Nord, AP-HM, Aix-Marseille Université, Marseille, France.
  • Roux A; Service de Pneumologie, Institut du Thorax, CHU Nantes, Nantes, France.
  • Le Pavec J; Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Eur Respir J ; 61(1)2023 01.
Article en En | MEDLINE | ID: mdl-36265877
QUESTION ADDRESSED BY THE STUDY: Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients? METHODS: We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre >264 BAU·mL-1 after the third dose (median (interquartile range (IQR)) 3.0 (1.7-4.1) months), was the primary outcome and adverse events were the secondary outcomes. Median (IQR) age at the first vaccine dose was 54 (40-63) years and median (IQR) time from transplantation to the first dose was 64 (30-110) months. RESULTS: Median (IQR) follow-up after the first dose was 8.3 (6.7-9.3) months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47/898 (5%)) and four (4/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1-7.3) months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease. CONCLUSIONS: Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection via cellular immunity and/or good adherence to shielding measures.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Eur Respir J Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Eur Respir J Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido